The reset in fair value for aTyr Pharma from about 114.29 to 45.17 highlights a sharply revised view of the modeled equity value per share. Recent Street research links this kind of adjustment to a more cautious stance a
Why Is aTyr Pharma, Inc. (ATYR) Stock Down Today?
Updated Nov 17, 2026 7:30 PM ET · Prev Close $5.24
Primary Move Catalyst & Conviction
65% Signal ConvictionBiotechnology & Biological Products sector moving together
This appears to be a sector-wide move. The Biotechnology & Biological Products sector is down 2.2% on average.
Market & Sector Relative Strength
ATYR lagging the S&P 500 by -5.01%Options Flow & Execution Desk
Bullish Flow · P/C 0.13Recent ATYR Catalyst Headlines
Verified WireSan Diego, Nov. 11, 2026 Globe Newswire -- aTyr Pharma, Inc. Nasdaq ATYR , a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase
San Diego Ap San Diego Ap Atyr Pharma Inc. ATYR on Thursday reported a loss of 18.
Reached alignment with FDA on proposed Phase 3 study of efzofitimod in pulmonary sarcoidosis with restrictive lung disease utilizing FVC as primary endpoint study-related activities initiated. Company to prioritize strat
1–3 Day Expected Range & Key Level
45% Follow-ThroughWatch for breakdown below $4.93
Technical Regime (ATYR)
1-Year Historical Move Analogs
5 EventsSessions in the past year where ATYR moved >3.0% down:
Retail & Crowd Sentiment
NeutralModerna's international revenue reached $900 million in the first nine months of 2026, making up about 40% of third-quarter revenue. Moderna earned an operating profit in the third quarter of 2026, but still lost money on operations over the last twelve months.
About aTyr Pharma, Inc.
aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality an...
Get Instant ATYR Catalyst Alerts
Receive an email alert when ATYR triggers an unusual volume breakout, options sweep, or rating shift.
Other Liquid Stocks Moving Today
All Today's MoversATYR Session & Catalyst FAQ
Why is ATYR stock down today?
This appears to be a sector-wide move. The Biotechnology & Biological Products sector is down 2.2% on average.
Is ATYR stock a buy or sell right now?
Today's session carries a 65% catalyst conviction score on 0.10x relative volume (low participation). Our multi-factor model currently rates ATYR as EXTENDED. Review full valuation, quality, and timing signals on the ATYR Buy or Sell Decision Brief →
What is ATYR's intrinsic value and expected trading range?
At $4.93, ATYR's modeled 1-to-3 session range is $4.78 – $5.03, with a key inflection level at $4.68 (support). Compare current price against multi-year cash flow projections in the ATYR Intrinsic Value & DCF Model → and Market Cycle Phase Tracker →
What do RSI and moving averages signal for ATYR?
RSI at 57.9 reflects constructive bullish momentum.
Tradestie Flagship Research & Market Hubs
Live institutional catalyst tape ranking liquid gainers, losers, options sweeps, and RVOL surges.
Track spot H100/B200 compute rental rates and frontier LLM inference token economics.
Wafer yield, CoWoS packaging, and HBM bill-of-materials teardown models across AI accelerators.
Monitor engineering velocity and upstream foundry wafer demand inflections across tech leaders.
Live conviction tracking, invalidation guardrails, and thesis health checks on flagship ideas.
Backtest-validated unusual options positioning and open-interest accumulation setups.
Daily ranked quantitative leaderboard with audited forward-return track record vs S&P 500.
High-yield, quality-screened cash-secured put and put-spread income candidates.